| Name | Title | Contact Details |
|---|
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
RIO attains its goal of improving the quality of life of disabled persons by providing comprehensive, coordinated programs which increase the ability of disabled individuals to function at home and at school, on the job, and in the community. RIO was established in 1950 to serve the multi-faceted needs of persons with functional disabilities caused by birth defects, medical condition or accidents. Services are provided without regard to age, race, creed, sexual orientation, and gender.
Rippl is a new kind of mental health company focused on seniors and obsessed with its clinicians. Seniors with mental health challenges, especially neurocognitive conditions like Alzheimer`s disease and other dementias, are overlooked and under cared for, often without access to high quality, real-time, practical care.
Kern Family Health Care is a Bakersfield, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nightengale Home Healthcare Inc is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.